The Journal and Authors retract the 8 February 2021 article cited above for the following reasons provided by the Authors:
Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies.
This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.
Summary
Keywords
PDAC, Ect2, EGFR, GRB2, EMT, Ubiquitination
Citation
Frontiers Editorial Office (2021) Retraction: ECT2 Increases the Stability of EGFR and Tumorigenicity by Inhibiting Grb2 Ubiquitination in Pancreatic Cancer. Front. Oncol. 11:734761. doi: 10.3389/fonc.2021.734761
Received
01 July 2021
Accepted
01 July 2021
Published
19 July 2021
Volume
11 - 2021
Edited and reviewed by
Giuseppe Giaccone, Cornell University, United States
Updates
Copyright
© 2021 Frontiers Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, editorial.office@frontiersin.org
This article was submitted to Gastrointestinal Cancers, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.